Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 4 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Regorafenib a promising treatment for metastatic colorectal cancer

Tristan Manalac
26 Nov 2017

Regorafenib appears to have promising efficacy as a third- or fourth-line treatment for patients with metastatic colorectal cancer (mCRC), according to a new study from Macau presented at the recently concluded European Society for Medical Oncology Asia 2017 Congress (ESMO Asia 2017).

The research team performed a retrospective review of the medical records of 36 mCRC patients (median age 58 years; 53 percent male) who received regorafenib monotherapy. All participants had prior palliative chemotherapy treatment regimens containing oxaliplatin, irinotecan and fluorouracil with biologics such as bevacizumab or cetuximab.

Majority of the patients were administered regorafenib at 160 mg/day (41 percent), while the others received a daily dose of 120 mg (28 percent) or 80 mg (31 percent).

Of the 36 participants, 45 percent had one to two prior lines of mCRC treatment, 34 percent had three and 21 percent had at least four; 90 percent received prior targeted therapies. Colon cancer was reported in 30, while the remaining 6 had rectal cancer. [ESMO Asia, abstract 152P]

Over a median treatment duration of 4.5 months, 17 patients achieved disease control corresponding to a rate of 47.2 percent.

Compared with those who did not receive the drug, those treated with third- or fourth-line regorafenib had longer median overall survival after the failure of standardized treatment (3.8 vs 8.0 months).

Overall survival from the diagnosis of unresectable mCRC following curative resection was likewise longer for those who were administered regorafenib than for those who were not (18.9 vs 34.9 months).

In the study sample, the most common adverse event was any grade of hand-foot-skin reaction, observed in 69.4 percent of the participants; grade 3 of this adverse event was observed in 30.5 percent. This was followed by fatigue (41.6 percent), liver function abnormalities (38.9 percent), mucositis (36.1 percent), rashes (36.1 percent), diarrhoea (33.3 percent) and hyperbilirubinemia (27.7 percent).

Other adverse events included bleeding (5.6 percent), hypertension (16.6 percent), nausea (16.9 percent) and anorexia (22.2 percent).

There were four grade 4 adverse events: elevated aspartate transaminase (2.7 percent) and alanine transaminase (2.7 percent) levels, hypertension (2.7 percent), and hyperbilirubinemia (5.5 percent). No treatment-related deaths were reported.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 4 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).